131 related articles for article (PubMed ID: 1330446)
1. Urokinase-catalyzed plasminogen activation at the monocyte/macrophage cell surface: a localized and regulated proteolytic system.
Vassalli JD; Wohlwend A; Belin D
Curr Top Microbiol Immunol; 1992; 181():65-86. PubMed ID: 1330446
[No Abstract] [Full Text] [Related]
2. Regulation and interactions in the activation of cell-associated plasminogen.
Myöhänen H; Vaheri A
Cell Mol Life Sci; 2004 Nov; 61(22):2840-58. PubMed ID: 15558213
[TBL] [Abstract][Full Text] [Related]
3. Urokinase-type plasminogen-activator receptor associates to a cell surface molecule in monocytic cells.
Ragno P; Montuori N; Rossi G
Biochem Biophys Res Commun; 1996 Jul; 224(1):252-7. PubMed ID: 8694822
[TBL] [Abstract][Full Text] [Related]
4. Urokinase-type plasminogen activator and its receptor in bladder cancer.
Hasui Y; Osada Y
J Natl Cancer Inst; 1997 May; 89(10):678-9. PubMed ID: 9168177
[No Abstract] [Full Text] [Related]
5. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes.
Stoppelli MP; Corti A; Soffientini A; Cassani G; Blasi F; Assoian RK
Proc Natl Acad Sci U S A; 1985 Aug; 82(15):4939-43. PubMed ID: 2991901
[TBL] [Abstract][Full Text] [Related]
6. Modulation of expression of monocyte/macrophage plasminogen activator activity and its implications for attenuation of vasculopathy.
Lundgren CH; Sawa H; Sobel BE; Fujii S
Circulation; 1994 Oct; 90(4):1927-34. PubMed ID: 7923681
[TBL] [Abstract][Full Text] [Related]
7. [Increase of the membrane-bound urokinase level in monocytes from patients with atherosclerosis is accompanied by decrease of urokinase-induced myocyte migration].
Arefieva TI; Krasnikova TL; Parfenova EV; Alekseeva IA
Biull Eksp Biol Med; 1998 Aug; 126(8):147-9. PubMed ID: 9777222
[No Abstract] [Full Text] [Related]
8. The plasminogen activator system: biology and regulation.
Irigoyen JP; Muñoz-Cánoves P; Montero L; Koziczak M; Nagamine Y
Cell Mol Life Sci; 1999 Oct; 56(1-2):104-32. PubMed ID: 11213252
[TBL] [Abstract][Full Text] [Related]
9. Urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes are not internalized upon binding to the urokinase-type-plasminogen-activator receptor in THP-1 cells. Interaction of urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes with the cell surface.
Ragno P; Montuori N; Rossi G
Eur J Biochem; 1995 Oct; 233(2):514-9. PubMed ID: 7588796
[TBL] [Abstract][Full Text] [Related]
10. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
[TBL] [Abstract][Full Text] [Related]
11. Initiation of plasminogen activation on the surface of monocytes expressing the type II transmembrane serine protease matriptase.
Kilpatrick LM; Harris RL; Owen KA; Bass R; Ghorayeb C; Bar-Or A; Ellis V
Blood; 2006 Oct; 108(8):2616-23. PubMed ID: 16794252
[TBL] [Abstract][Full Text] [Related]
12. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.
Vines DJ; Lee SW; Dichek DA; Ellis V
J Pept Sci; 2000 Sep; 6(9):432-9. PubMed ID: 11016879
[TBL] [Abstract][Full Text] [Related]
13. A novel, specific pro-urokinase complex on monocyte-like cells, detected by transglutaminase-catalyzed cross-linking.
Behrendt N; Rønne E; Danø K
FEBS Lett; 1993 Dec; 336(3):394-6. PubMed ID: 7904248
[TBL] [Abstract][Full Text] [Related]
14. Prognostic relevance of urokinase type plasminogen activator, its receptor and inhibitors in chondrosarcoma.
Morii T; Yabe H; Morioka H; Yamada R; Nakagawa T; Toyama Y
Anticancer Res; 2000; 20(5A):3031-6. PubMed ID: 11062719
[TBL] [Abstract][Full Text] [Related]
15. Expression of urokinase, plasminogen activator inhibitors and urokinase receptor in pregnant rhesus monkey uterus during early placentation.
Feng Q; Liu Y; Liu K; Byrne S; Liu G; Wang X; Li Z; Ockleford CD
Placenta; 2000; 21(2-3):184-93. PubMed ID: 10736241
[TBL] [Abstract][Full Text] [Related]
16. Processing of complex between urokinase and its type-2 inhibitor on the cell surface. A possible regulatory mechanism of urokinase activity.
Ragno P; Montuori N; Vassalli JD; Rossi G
FEBS Lett; 1993 Jun; 323(3):279-84. PubMed ID: 8388810
[TBL] [Abstract][Full Text] [Related]
17. [The clinical prospects for the study of the plasminogen activation system in breast cancer].
Gershteĭn ES; Kushlinskiĭ NE
Vestn Ross Akad Med Nauk; 1999; (8):58-61. PubMed ID: 10487126
[TBL] [Abstract][Full Text] [Related]
18. Retinoic acid potentiates phorbol ester-mediated induction of urokinase and plasminogen activator inhibitor type 2 in human myeloid leukemic cell lines.
Schuster WA; Medcalf RL; Kruithof EK
Endocrinology; 1993 Oct; 133(4):1724-30. PubMed ID: 8404615
[TBL] [Abstract][Full Text] [Related]
19. Expression and localization of the urokinase-type plasminogen activator receptor (uPAR) in the human placenta.
Nishida Y; Hayashi Y; Imai Y; Itoh H
Kobe J Med Sci; 1998 Feb; 44(1):31-43. PubMed ID: 9846056
[TBL] [Abstract][Full Text] [Related]
20. Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.
Shiomi H; Eguchi Y; Tani T; Kodama M; Hattori T
Am J Pathol; 2000 Feb; 156(2):567-75. PubMed ID: 10666386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
